HR 2212
115th Congress
House
Health
Civil actions and liability
Drug safety, medical device, and laboratory regulation
Licensing and registrations
Prescription drugs
Product development and innovation
CREATES Act of 2017
Introduced: April 27, 2017
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 28, 2017
Referred to the Subcommittee on Health.
Apr 27, 2017
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 27, 2017
Introduced in House
Plain-English summary
Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017
This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
3